The DOI matches its Crossref record; 43 of the 43 references it cites were found in a registry or an index.
Antiemetics: American Society of Clinical Oncology Clinical Practice Guideline Update
Open accessAbstract
Purpose: To update the American Society of Clinical Oncology (ASCO) guideline for antiemetics in oncology. Methods: A systematic review of the medical literature was completed to inform this update. MEDLINE, the Cochrane Collaboration Library, and meeting materials from ASCO and the Multinational Association for Supportive Care in Cancer were all searched. Primary outcomes of interest were complete response and rates of any vomiting or nausea. Results: Thirty-seven trials met prespecified inclusion and exclusion criteria for this systematic review. Two systematic reviews from the Cochrane Collaboration were identified; one surveyed the pediatric literature. The other compared the relative efficacy of the 5-hydroxytryptamine-3 (5-HT 3 ) receptor antagonists. Recommendations: Combined anthracycline and cyclophosphamide regimens were reclassified as highly emetic. Patients who receive this combination or any highly emetic agents should receive a 5-HT 3 receptor antagonist, dexamethasone, and a neurokinin 1 (NK 1 ) receptor antagonist. A large trial validated the equivalency of fosaprepitant, a single-day intravenous formulation, with aprepitant; either therapy is appropriate. Preferential use of palonosetron is recommended for moderate emetic risk regimens, combined with dexamethasone. For low-risk agents, patients can be offered dexamethasone before the first dose of chemotherapy. Patients undergoing high emetic risk radiation therapy should receive a 5-HT 3 receptor antagonist before each fraction and for 24 hours after treatment and may receive a 5-day course of dexamethasone during fractions 1 to 5. The Update Committee noted the importance of continued symptom monitoring throughout therapy. Clinicians underestimate the incidence of nausea, which is not as well controlled as emesis.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
2 retracted
Acupuncture-point stimulation for chemotherapy-induced nausea or vomiting
Ezzo, J., Richardson, M. A., Vickers, A., Allen, C., Dibble, S., Issell, B. F., Lao, L., Pearl, M., Ramirez, G., Roscoe, J. A., et al. (2006) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd002285.pub2 · Cited by 341
RetractedSerotonin receptor antagonists for highly emetogenic chemotherapy in adults
Billio, A., Morello, E., & Clarke, M. J. (2010) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd006272.pub2 · Cited by 68
RetractedSEER Cancer Statistics Review, 1975-2003
Ries, L. A. G., Harkins, D., Krapcho, M. F., Mariotto, A. B., Miller, B., Feuer, E. J., Clegg, L. X., Eisner, M. P., Horner, M., Howlader, N., et al. (2006) · Digital Archive @ GSU · Cited by 11,775
U.S. Department of Health and Human Services FDA Center for Drug Evaluation and Research, U.S. Department of Health and Human Services FDA Center for Biologics Evaluation and Research, & U.S. Department of Health and Human Services FDA Center for Devices and Radiological Health (2006) · Health and Quality of Life Outcomes · doi:10.1186/1477-7525-4-79 · Cited by 2,856
Improved Survival with MEK Inhibition in BRAF-Mutated Melanoma
Flaherty, K. T., Robert, C., Hersey, P., Nathan, P., Garbe, C., Milhem, M., Demidov, L. V., Hassel, J. C., Rutkowski, P., Mohr, P., et al. (2012) · New England Journal of Medicine · doi:10.1056/nejmoa1203421 · Cited by 2,160
Improved survival with MEK Inhibition in BRAF-mutated melanoma for the METRIC Study Group
Flaherty, K. T., Robert, C., Hersey, P., Nathan, P., Garbe, C., Milhem, M. M., Демидов, Л. В., Hassel, J. C., Rutkowski, P. L., Mohr, P., et al. (2012) · Zurich Open Repository and Archive (University of Zurich) · doi:10.5167/uzh-63198 · Cited by 1,330
How Quickly Do Systematic Reviews Go Out of Date? A Survival Analysis
Shojania, K. G., Sampson, M., Ansari, M. T., Ji, J., Doucette, S., & Moher, D. (2007) · Annals of Internal Medicine · doi:10.7326/0003-4819-147-4-200708210-00179 · Cited by 838
American Society of Clinical Oncology Guideline for Antiemetics in Oncology: Update 2006
Kris, M. G., Hesketh, P. J., Somerfield, M. R., Feyer, P., Clark-Snow, R., Koeller, J. M., Morrow, G. R., Chinnery, L. W., Chesney, M. J., Gralla, R. J., et al. (2006) · Journal of Clinical Oncology · doi:10.1200/jco.2006.06.9591 · Cited by 740
Self-citationRoila, F., Herrstedt, J., Aapro, M., Gralla, R. J., Einhorn, L. H., Ballatori, E., Bria, E., Clark-Snow, R. A., Espersen, B. T., Feyer, P., et al. (2010) · Annals of Oncology · doi:10.1093/annonc/mdq194 · Cited by 680
Self-citationRecommendations for the Use of Antiemetics: Evidence-Based, Clinical Practice Guidelines
Gralla, R. J., Osoba, D., Kris, M. G., Kirkbride, P., Hesketh, P. J., Chinnery, L. W., Clark-Snow, R., Gill, D. P., Groshen, S., Grunberg, S., et al. (1999) · Journal of Clinical Oncology · doi:10.1200/jco.1999.17.9.2971 · Cited by 664
Self-citationThe Missing Voice of Patients in Drug-Safety Reporting
Basch, E. (2010) · New England Journal of Medicine · doi:10.1056/nejmp0911494 · Cited by 646
Self-citationAmerican Society of Clinical Oncology Guidance Statement: The Cost of Cancer Care
Meropol, N. J., Schrag, D., Smith, T. J., Mulvey, T. M., Langdon, R. M., Blum, D., Ubel, P. A., & Schnipper, L. E. (2009) · Journal of Clinical Oncology · doi:10.1200/jco.2009.23.1183 · Cited by 638
Proposal for classifying the acute emetogenicity of cancer chemotherapy.
Hesketh, P. J., Kris, M. G., Grunberg, S. M., Beck, T., Hainsworth, J. D., Harker, G., Aapro, M. S., Gandara, D., & Lindley, C. M. (1997) · Journal of Clinical Oncology · doi:10.1200/jco.1997.15.1.103 · Cited by 605
Self-citationWarr, D. G., Hesketh, P. J., Gralla, R. J., Muss, H. B., Herrstedt, J., Eisenberg, P. D., Raftopoulos, H., Grunberg, S. M., Gabriel, M., Rodgers, A., et al. (2005) · Journal of Clinical Oncology · doi:10.1200/jco.2005.09.050 · Cited by 463
Self-citationLimits on Medicare's Ability to Control Rising Spending on Cancer Drugs
Bach, P. B. (2009) · New England Journal of Medicine · doi:10.1056/nejmhpr0807774 · Cited by 390
Aapro, M. S., Grunberg, S. M., Manikhas, G. M., Olivares, G., Suarez, T., Tjulandin, S. A., Bertoli, L. F., Yunus, F., Morrica, B., Lordick, F., et al. (2006) · Annals of Oncology · doi:10.1093/annonc/mdl137 · Cited by 338
Yoshino, T., Mizunuma, N., Yamazaki, K., Nishina, T., Komatsu, Y., Baba, H., Tsuji, A., Yamaguchi, K., Muro, K., Sugimoto, N., et al. (2012) · The Lancet Oncology · doi:10.1016/s1470-2045(12)70345-5 · Cited by 326
(2006) · Annals of Oncology · doi:10.1093/annonc/mdj078 · Cited by 323
Aapro, M., Molassiotis, A., Dicato, M., Peláez, I., Rodríguez-Lescure, Á., Pastorelli, D., Ma, L., Burke, T., Gu, A., Gascon, P., et al. (2012) · Annals of Oncology · doi:10.1093/annonc/mds021 · Cited by 308
Ryan, J. L., Heckler, C. E., Roscoe, J. A., Dakhil, S. R., Kirshner, J., Flynn, P. J., Hickok, J. T., & Morrow, G. R. (2012) · Supportive Care in Cancer · doi:10.1007/s00520-011-1236-3 · Cited by 267
Self-citationPatient and Plan Characteristics Affecting Abandonment of Oral Oncolytic Prescriptions
Streeter, S. B., Schwartzberg, L., Husain, N., & Johnsrud, M. (2011) · Journal of Oncology Practice · doi:10.1200/jop.2011.000316 · Cited by 248
Rapoport, B. L., Jordan, K., Boice, J. A., Taylor, A., Brown, C., Hardwick, J. S., Carides, A., Webb, T., & Schmoll, H.-J. (2010) · Supportive Care in Cancer · doi:10.1007/s00520-009-0680-9 · Cited by 229
(2008) · Cited by 225
Grunberg, S., Chua, D., Maru, A., Dinis, J., DeVandry, S., Boice, J. A., Hardwick, J. S., Beckford, E., Taylor, A., Carides, A., et al. (2011) · Journal of Clinical Oncology · doi:10.1200/jco.2010.31.7859 · Cited by 217
Batist, G., Gelmon, K. A., Chi, K. N., Miller, W. H., Chia, S. K. L., Mayer, L. D., Swenson, C. E., Janoff, A. S., & Louie, A. C. (2009) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-08-0515 · Cited by 213
Hickok, J. T., Roscoe, J. A., Morrow, G. R., King, D. K., Atkins, J. N., & Fitch, T. R. (2003) · Cancer · doi:10.1002/cncr.11408 · Cited by 208
Self-citationClinical research of Olanzapine for prevention of chemotherapy-induced nausea and vomiting
Tan, L., Liu, J., Liu, X., Chen, J., Yan, Z., Yang, H., & Zhang, D. (2009) · Journal of Experimental & Clinical Cancer Research · doi:10.1186/1756-9966-28-131 · Cited by 201
Shiffman, R. N., Michel, G., Rosenfeld, R. M., & Davidson, C. (2012) · Journal of the American Medical Informatics Association · doi:10.1136/amiajnl-2011-000172 · Cited by 184
Phase II trial of encapsulated ginger as a treatment for chemotherapy-induced nausea and vomiting
Zick, S. M., Ruffin, M. T., Lee, J., Normolle, D. P., Siden, R., Alrawi, S., & Brenner, D. E. (2009) · Supportive Care in Cancer · doi:10.1007/s00520-008-0528-8 · Cited by 167
Pillai, A. K., Sharma, K. K., Gupta, Y. K., & Bakhshi, S. (2011) · Pediatric Blood & Cancer · doi:10.1002/pbc.22778 · Cited by 164
Phillips, R. S., Friend, A. J., Gibson, F., Houghton, E., Gopaul, S., Craig, J. V., & Pizer, B. L. (2016) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd007786.pub3 · Cited by 135
Racial and Ethnic Disparities in Care: The Perspectives of Cardiologists
Lurie, N., Fremont, A., Jain, A. K., Taylor, S. L., McLaughlin, R., Peterson, E., Kong, B. W., & Ferguson, T. B. (2005) · Circulation · doi:10.1161/01.cir.0000157738.12783.71 · Cited by 109
Albany, C., Brames, M. J., Fausel, C. A., Johnson, C. S., Picus, J., & Einhorn, L. H. (2012) · Journal of Clinical Oncology · doi:10.1200/jco.2011.39.5558 · Cited by 108
Gore, L., Chawla, S. P., Petrilli, A. S., Hemenway, M. S., Schissel, D., Chua, V., Carides, A. D., Taylor, A., DeVandry, S., Valentine, J. L., et al. (2008) · Pediatric Blood & Cancer · doi:10.1002/pbc.21811 · Cited by 96
Jordan, K., Hinke, A., Grothey, A., Voigt, W., Arnold, D., Wolf, H.-H., & Schmoll, H.-J. (2007) · Supportive Care in Cancer · doi:10.1007/s00520-006-0186-7 · Cited by 93
on behalf of the Sancuso Study Group, Boccia, R. V., Gordan, L., Clark, G., Howell, J. D., & Grunberg, S. M. (2010) · Supportive Care in Cancer · doi:10.1007/s00520-010-0990-y · Cited by 84
Kirkbride, P., Bezjak, A., Pater, J. L., Zee, B. C.-Y., Palmer, M., Wong, R. K. S., Cross, P., Gulavita, S. P. P., Blood, P. A., Sun, A. Y., et al. (2000) · Journal of Clinical Oncology · doi:10.1200/jco.2000.18.9.1960 · Cited by 81
Wong, R. K. S., Paul, N., Ding, K., Whitehead, M., Brundage, M., Fyles, A., Wilke, D., Nabid, A., Fortin, A., Wilson, D., et al. (2006) · Journal of Clinical Oncology · doi:10.1200/jco.2005.04.4685 · Cited by 63
Ryan, J. L., Heckler, C. E., Dakhil, S. R., Kirshner, J. J., Flynn, P. J., Hickok, J. T., & Morrow, G. R. (2009) · Journal of Clinical Oncology · doi:10.1200/jco.2009.27.15_suppl.9511 · Cited by 53
Self-citationPhillips, R. S., Gopaul, S., Gibson, F., Houghton, E., Craig, J. V., Light, K., & Pizer, B. L. (2010) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd007786.pub2 · Cited by 40
Gomez, D. R., Liao, K.-P. E., Giordano, S. H., Nguyen, H., Smith, B. D., & Elting, L. S. (2012) · Cancer · doi:10.1002/cncr.27899 · Cited by 36
Abbott, B. L., Ippoliti, C. M., Bruton, J., Neumann, J. L., Whaley, R., & Champlin, R. (1999) · Bone Marrow Transplantation · doi:10.1038/sj.bmt.1701565 · Cited by 31
Fabi, A., Ciccarese, M., Metro, G., Savarese, A., Giannarelli, D., Nuzzo, C. M. A., Russillo, M., Sperduti, I., Carbone, I., Bria, E., et al. (2008) · Supportive Care in Cancer · doi:10.1007/s00520-008-0438-9 · Cited by 12
Cited by
Baracos, V. E., Martin, L., Korc, M., Guttridge, D. C., & Fearon, K. C. H. (2018) · Nature Reviews Disease Primers · doi:10.1038/nrdp.2017.105 · Cited by 1,738
Preventing and Managing Toxicities of High-Dose Methotrexate
Howard, S. C., McCormick, J., Pui, C.-H., Buddington, R. K., & Harvey, R. D. (2016) · The Oncologist · doi:10.1634/theoncologist.2015-0164 · Cited by 929
Antiemetics: American Society of Clinical Oncology Clinical Practice Guideline Update
Hesketh, P. J., Kris, M. G., Basch, E., Bohlke, K., Barbour, S. Y., Clark-Snow, R. A., Danso, M. A., Dennis, K., Dupuis, L. L., Dusetzina, S. B., et al. (2017) · Journal of Clinical Oncology · doi:10.1200/jco.2017.74.4789 · Cited by 628
Self-citationAntiemetics: ASCO Guideline Update
Hesketh, P. J., Kris, M. G., Basch, E., Bohlke, K., Barbour, S. Y., Clark-Snow, R. A., Danso, M. A., Dennis, K., Dupuis, L. L., Dusetzina, S. B., et al. (2020) · Journal of Clinical Oncology · doi:10.1200/jco.20.01296 · Cited by 470
Self-citationOlanzapine for the prevention of chemotherapy-induced nausea and vomiting.
Navari, R. M., Qin, R., Ruddy, K. J., Liu, H., Powell, S. F., Bajaj, M., Dietrich, L., Biggs, D., Lafky, J. M., & Loprinzi, C. L. (2016) · New England Journal of Medicine · doi:10.1056/nejmoa1515725 · Cited by 452
Metadata
- Authors
- Basch, E., Prestrud, A. A., Hesketh, P. J., Kris, M. G., Feyer, P. C., Somerfield, M. R., Chesney, M., Clark-Snow, R. A., Flaherty, A. M., Freundlich, B., Morrow, G., Rao, K. V., Schwartz, & Lyman, G. H.
- Venue
- Journal of Clinical Oncology
- Published
- 2011-11-01
- Volume
- 29
- Issue
- 31
- Pages
- 4189-4198
- ISSN
- 0732-183X (ISSN-L)
- 1527-7755
- OpenAlex
- W2123267000
- Cited by
- 1,059
- References
- 43
- FWCI
- 81.36
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.